Global Information
회사소개 | 문의 | 비교리스트

암 지지요법 약제 시장 기회 분석 및 산업 예측(2021-2030년) : 유형, 용도, 유통경로별

Cancer Supportive Care Drugs Market by Type, Application, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030.

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059625
페이지 정보 영문 261 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



암 지지요법 약제 시장 기회 분석 및 산업 예측(2021-2030년) : 유형, 용도, 유통경로별 Cancer Supportive Care Drugs Market by Type, Application, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030.
발행일 : 2021년 12월 페이지 정보 : 영문 261 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 암 지지요법 약제 시장 규모는 2020년 196억 3,370만 달러에서 예측기간에는 2.2%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 244억 760만 달러 규모로 성장할 것으로 예측됩니다.

암 유병률 상승, 항암제 사용에 따른 부작용 증가, 세계 고령자 인구 급증, 바이오시밀러 보급, 정부의 의료비 부담 증가 등의 요인이 시장 성장의 원동력이 되고 있습니다. R&D 및 파이프라인 증가, 미개척 신흥 국가의 높은 성장 가능성 또한 시장에 유리한 성장 기회를 나타낼 것으로 예상되고 있습니다. 한편, 부작용이 적은 표적 치료제가 개발되고, 환자나 의사로부터 지지를 받고 있는 것이 시장 성장을 방해하고 있습니다. 바이오시밀러 의약품 승인을 위한 엄격한 규제 프로세스도 시장 성장을 억제할 것으로 예상됩니다.

세계의 암 지지요법 약제(Cancer Supportive Care Drugs) 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모 추이와 예측, 유형·용도·유통경로·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
  • Porter의 산업 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석
  • COVID-19 : 영향 분석

제4장 암 지지요법 약제 : 유형별

  • 개요
  • ESAs (Erythropoiesis stimulating agent)
  • G-CSFs (Granulocyte colony-stimulating factors)
  • 구토제
  • 비스포스포네이트
  • 오피오이드
  • NSAID(Non-Steroidal auto inflammatory drugs)
  • 기타
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모와 예측
    • 시장 분석 : 국가별

제5장 암 지지요법 약제 : 용도별

  • 개요
  • 유방암
  • 폐암
  • 결장직장
  • 전립선
  • 간암
  • 위암
  • 기타
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제6장 암 지지요법 약제 : 유통경로별

  • 개요
  • 병원 약국
  • 드럭스토어/소매 약국
  • 온라인 프로바이더
    • 시장 규모와 예측
    • 시장 분석 : 국가별

제7장 암 지지요법 약제 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모와 예측 : 국가별
    • 시장 규모와 예측 : 유형별
    • 시장 규모와 예측 : 용도별
    • 시장 규모와 예측 : 유통경로별

제8장 기업 개요

  • AMGEN INC.
  • BAXTER INTERNATIONAL INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • GLAXOSMITHKLINE PLC(GSK)(TESASRO)
  • HELSINN HEALTHCARE
  • HERON THERAPEUTICS
  • JOHNSON & JOHNSON(JANSSEN GLOBAL SERVICES, LLC,)
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG(SANDOZ)
  • TEVA PHARMACEUTICALS
LSH 22.03.10

LIST OF TABLES

  • TABLE 01.GLOBAL CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 02.CANCER SUPPORTIVE CARE DRUGS FOR ERYTHROPOIESIS STIMULATING AGENT (ESAS), BY REGION,

2020-2030 ($MILLION)

  • TABLE 03.CANCER SUPPORTIVE CARE DRUGS FOR GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSFS),

BY REGION, 2020-2030 ($MILLION)

  • TABLE 04.CANCER SUPPORTIVE CARE DRUGS FOR ANTIEMETICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.CANCER SUPPORTIVE CARE DRUGS FOR BISPHOSPHONATES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.CANCER SUPPORTIVE CARE DRUGS FOR OPIOIDS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.CANCER SUPPORTIVE CARE DRUGS FOR NSAIDS (NON-STEROIDAL AUTO INFLAMMATORY DRUGS),

BY REGION, 2020-2030 ($MILLION)

  • TABLE 08.CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.GLOBAL CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 10.CANCER SUPPORTIVE CARE DRUGS FOR BREAST, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.CANCER SUPPORTIVE CARE DRUGS FOR LUNG, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.CANCER SUPPORTIVE CARE DRUGS FOR COLORECTAL, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.CANCER SUPPORTIVE CARE DRUGS FOR PROSTATE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.CANCER SUPPORTIVE CARE DRUGS FOR LIVER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.CANCER SUPPORTIVE CARE DRUGS FOR STOMACH, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.GLOBAL CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 18.CANCER SUPPORTIVE CARE DRUGS FOR HOSPITAL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 19.CANCER SUPPORTIVE CARE DRUGS FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION,
  • 2020-2030 ($MILLION)
  • TABLE 20.CANCER SUPPORTIVE CARE DRUGS FOR ONLINE PROVIDERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 21.CANCER SUPPORTIVE CARE DRUGS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 22.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 23.U.S. CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 24.U.S. CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 25.U.S. CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 26.CANADA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 27.CANADA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 28.CANADA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 29.MEXICO CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 30.MEXICO CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 31.MEXICO CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 32.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 33.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 34.NORTH AMERICA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 35.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 36.GERMANY CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 37.GERMANY CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 38.GERMANY CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 39.FRANCE CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 40.FRANCE CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 41.FRANCE CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 42.UK CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 43.UK CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 44.UK CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 45.ITALY CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 46.ITALY CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 47.ITALY CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 48.SPAIN CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 49.SPAIN CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 50.SPAIN CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 51.REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 52.REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 53.REST OF EUROPE CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 54.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 55.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 56.EUROPE CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 57.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 58.JAPAN CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 59.JAPAN CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 60.JAPAN CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 61.CHINA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 62.CHINA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 63.CHINA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 64.AUSTRALIA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 65.AUSTRALIA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 66.AUSTRALIA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 67.INDIA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 68.INDIA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 69.INDIA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 70.SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 71.SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 72.SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030
  • ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 74.REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 75.REST OF ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 76.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 77.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 78.ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030
  • ($MILLION)
  • TABLE 79.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 80.BRAZIL CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 81.BRAZIL CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 82.BRAZIL CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 83.SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 84.SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 85.SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030
  • ($MILLION)
  • TABLE 86.SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 87.SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 88.SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL 2020-2030
  • ($MILLION)
  • TABLE 89.REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 90.REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 91.REST OF LAMEA CANCER SUPPORTIVE CARE DRUGS, DISTRIBUTION CHANNEL, 2020-2030
  • ($MILLION)
  • TABLE 92.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 93.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 94.LAMEA CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 95.AMGEN: COMPANY SNAPSHOT
  • TABLE 96.AMGEN: OPERATING SEGMENT
  • TABLE 97.AMGEN: PRODUCT PORTFOLIO
  • TABLE 98.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99.BAXTER: COMPANY SNAPSHOT
  • TABLE 100.BAXTER: BUSINESS UNITS
  • TABLE 101.BAXTER: PRODUCT PORTFOLIO
  • TABLE 102.ROCHE: COMPANY SNAPSHOT
  • TABLE 103.ROCHE: OPERATING SEGMENTS
  • TABLE 104.ROCHE: PRODUCT PORTFOLIO
  • TABLE 105.GSK: COMPANY SNAPSHOT
  • TABLE 106.GSK: OPERATING SEGMENTS
  • TABLE 107.GSK: PRODUCT PORTFOLIO
  • TABLE 108.HELSINN: COMPANY SNAPSHOT
  • TABLE 109.HELSINN: OPERATING SEGMENTS
  • TABLE 110.HELSINN: PRODUCT PORTFOLIO
  • TABLE 111.HERON THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 112.HERON THERAPEUTICS: OPERATING SEGMENT
  • TABLE 113.HERON THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 114.HERON THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115.J&J: COMPANY SNAPSHOT
  • TABLE 116.J&J: OPERATING SEGMENTS
  • TABLE 117.J&J: PRODUCT TYPE PORTFOLIO
  • TABLE 118.MERCK: COMPANY SNAPSHOT
  • TABLE 119.MERCK: OPERATING SEGMENTS
  • TABLE 120.MERCK: PRODUCT PORTFOLIO
  • TABLE 121.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 122.NOVARTIS: OPERATING SEGMENTS
  • TABLE 123.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 124.TEVA: COMPANY SNAPSHOT
  • TABLE 125.TEVA: OPERATING SEGMENTS
  • TABLE 126.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 05.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07.HIGH INTENSITY OF RIVALRY
  • FIGURE 08.TOP PLAYER POSITIONING, 2020
  • FIGURE 09.IMPACT ANALYSIS
  • FIGURE 10.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR ESAS (ERYTHROPOIESIS

STIMULATING AGENT), BY COUNTRY, 2020 & 2030 (%)

  • FIGURE 11.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR G-CSFS (GRANULOCYTE

COLONY-STIMULATING FACTORS), BY COUNTRY, 2020 & 2030 (%)

  • FIGURE 12.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR ANTIEMETICS, BY COUNTRY,

2020 & 2030 (%)

  • FIGURE 13.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR BISPHOSPHONATES,

BY COUNTRY, 2020 & 2030 (%)

  • FIGURE 14.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR OPIOIDS, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR NSAIDS (NON-STEROIDAL
  • AUTO INFLAMMATORY DRUGS), BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS CANCER SUPPORTIVE CARE DRUGS FOR BREAST, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR LUNG, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR COLORECTAL, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR PROSTATE, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR SKIN, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR STOMACH, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR OTHERS, BY COUNTRY,
  • 2020 & 2030 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR HOSPITAL PHARMACIES,

BY COUNTRY, 2020 & 2030 (%)

  • FIGURE 25.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF CANCER SUPPORTIVE CARE DRUGS FOR ONLINE PROVIDERS,

BY COUNTRY, 2020 & 2030 (%)

  • FIGURE 27.AMGEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.AMGEN: REVENUE SHARE BY REGION, 2019(%)
  • FIGURE 29.BAXTER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 30.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 31.BAXTER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 32.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 33.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 34.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 35.GSK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 37.GSK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 38.HERON THERAPEUTICS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.J&J: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 40.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 41.J&J: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 42.MERCK: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.MERCK: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 44.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 45.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 46.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 47.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 48.TEVA.: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 49.TEVA: REVENUE SHARE BY REGION, 2020 (%)

The global cancer supportive care drugs market was valued at $19,633.7 million in 2020 and is projected to reach $24,407.6 million by 2030 registering a CAGR of 2.2% from 2021 to 2030.

Cancer supportive care drugs are used to mitigate the harmful side effects of cancer treatment by protecting certain cells or organs. Cancer supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases, cancer treatments need to be stopped or doses need to lower due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments come with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. With such side effects, there is preference to use supportive care drugs during cancer treatments.

The main driving factors that drive growth of the cancer supportive care drugs include, rise in prevalence of cancer and adverse effects associated with the use cancer drugs, as well as surge in global geriatric population. In addition, rise in uptake of biosimilars, and increase in government expenditure on healthcare further boost growth of the cancer supportive care drugs. However, increase in advancements in targeted therapy drugs that have lesser side effects are discovered and preferred by the patients and doctors which is directly affecting the growth of the cancer supportive care drugs which hamper the growth of market. Furthermore, Stringent regulatory process for biosimilar approval is also expected to limit growth of the market. In contrast, increase in R&D and number of pipeline cancer supportive care drugs, high growth potential in untapped emerging economies are some factors which expected to offer lucrative growth opportunities for players in the cancer supportive care drugs.

The global cancer supportive care drugs is segmented on the basis of type, application, distribution channel, and region to provide a detailed assessment of the market. By type, it is segmented into erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (Non-Steroidal auto inflammatory drugs), and others. By application, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others. Based on distribution channel, it is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the cancer supportive care drugs market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of cancer supportive care drugs used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

  • ESA (Erythropoiesis-Stimulating Agents)
  • G-CSFs (Granulocyte Colony-Stimulating Factors)
  • Antiemetics
  • Bisphosphonates
  • Opioids
  • NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
  • Others

By Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Liver Cancer
  • Stomach Cancer
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • AMGEN INC
  • BAXTER INTERNATIONAL INC
  • F. HOFFMANN-LA ROCHE LTD.
  • GLAXOSMITHKLINE PLC (GSK) (TESARO)
  • HELSINN HEALTHCARE
  • HERON THERAPEUTICS
  • JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG (SANDOZ)
  • TEVA PHARMACEUTICALS

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in prevalence of cancer and adverse effects associated with

use of cancer drugs

      • 3.5.1.2.Surge in global geriatric population
      • 3.5.1.3.Rise in uptake of biosimilars
      • 3.5.1.4.Increase in government expenditure on healthcare
    • 3.5.2.Restraints
      • 3.5.2.1.Advancements in targeted therapy drugs
      • 3.5.2.2.Stringent regulatory process for biosimilar approval
    • 3.5.3.Opportunities
      • 3.5.3.1.Increase in R&D and number of pipeline cancer supportive care drugs
      • 3.5.3.2.High growth potential in untapped emerging economies60
    • 3.5.4.Impact analysis
  • 3.6.COVID-19 Impact analysis on the cancer supportive care drugs

CHAPTER 4:CANCER SUPPORTIVE CARE DRUGS, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.ESAs (Erythropoiesis stimulating agent)
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.G-CSFs (Granulocyte colony-stimulating factors)
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Antiemetics
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Bisphosphonates
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country
  • 4.6.Opioids
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast
    • 4.6.3.Market analysis, by country
  • 4.7.NSAIDs (Non-Steroidal auto inflammatory drugs)
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast
    • 4.7.3.Market analysis, by country
  • 4.8.Others
    • 4.8.1.Key market trends, growth factors, and opportunities
    • 4.8.2.Market size and forecast
    • 4.8.3.Market analysis, by country

CHAPTER 5:CANCER SUPPORTIVE CARE DRUGS, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Breast Cancer
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Lung Cancer
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Colorectal
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Prostate
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country
  • 5.6.Liver Cancer
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis, by country
  • 5.7.Stomach
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis, by country
  • 5.8.Others
    • 5.8.1.Market size and forecast, by region
    • 5.8.2.Market analysis, by country

CHAPTER 6:CANCER SUPPORTIVE CARE DRUGS, BY DISTRIBUTION CHANNEL

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital Pharmacies
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Drug Stores and Retail Pharmacies
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Online Providers
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:CANCER SUPPORTIVE CARE DRUGS, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country124
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. cancer supportive care drugs, by type
      • 7.2.2.1.2.U.S. cancer supportive care drugs, by application
      • 7.2.2.1.3.U.S. cancer supportive care drugs, by distribution channel
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada cancer supportive care drugs, by type
      • 7.2.2.2.2.Canada cancer supportive care drugs, by application
      • 7.2.2.2.3.Canada cancer supportive care drugs, by distribution channel
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico cancer supportive care drugs, by type
      • 7.2.2.3.2.Mexico cancer supportive care drugs, by application
      • 7.2.2.3.3.Mexico cancer supportive care drugs, by distribution channel
    • 7.2.3.North America market size and forecast, by type
    • 7.2.4.North America market size and forecast, by application
    • 7.2.5.North America market size and forecast, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country141
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany cancer supportive care drugs, by type
      • 7.3.2.1.2.Germany cancer supportive care drugs, by application
      • 7.3.2.1.3.Germany cancer supportive care drugs, by distribution channel
      • 7.3.2.2.France
      • 7.3.2.2.1.France cancer supportive care drugs, by type
      • 7.3.2.2.2.France cancer supportive care drugs, by application
      • 7.3.2.2.3.France cancer supportive care drugs, by distribution channel
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK cancer supportive care drugs, by type
      • 7.3.2.3.2.UK cancer supportive care drugs, by application
      • 7.3.2.3.3.UK cancer supportive care drugs, by distribution channel
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy cancer supportive care drugs, by type
      • 7.3.2.4.2.Italy cancer supportive care drugs, by application
      • 7.3.2.4.3.Italy cancer supportive care drugs, by distribution channel
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain cancer supportive care drugs, by type
      • 7.3.2.5.2.Spain cancer supportive care drugs, by application
      • 7.3.2.5.3.Spain cancer supportive care drugs, by distribution

channel

      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe cancer supportive care drugs, by type
      • 7.3.2.6.2.Rest of Europe cancer supportive care drugs,

by application

      • 7.3.2.6.3.Rest of Europe cancer supportive care drugs,

by distribution channel

    • 7.3.3.Europe market size and forecast, by type
    • 7.3.4.Europe market size and forecast, by application
    • 7.3.5.Europe market size and forecast, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan cancer supportive care drugs, by type
      • 7.4.2.1.2.Japan cancer supportive care drugs, by application
      • 7.4.2.1.3.Japan cancer supportive care drugs, by distribution

channel

      • 7.4.2.2.China
      • 7.4.2.2.1.China cancer supportive care drugs, by type
      • 7.4.2.2.2.China cancer supportive care drugs, by application
      • 7.4.2.2.3.China cancer supportive care drugs, by distribution

channel

      • 7.4.2.3.Australia
      • 7.4.2.3.1.Australia cancer supportive care drugs, by type
      • 7.4.2.3.2.Australia cancer supportive care drugs, by application
      • 7.4.2.3.3.Australia cancer supportive care drugs, by distribution channel
      • 7.4.2.4.India
      • 7.4.2.4.1.India cancer supportive care drugs, by type
      • 7.4.2.4.2.India cancer supportive care drugs, by application
      • 7.4.2.4.3.India cancer supportive care drugs, by distribution

channel

      • 7.4.2.5.South Korea
      • 7.4.2.5.1.South Korea cancer supportive care drugs, by Type
      • 7.4.2.5.2.South Korea cancer supportive care drugs, by application
      • 7.4.2.5.3.South Korea cancer supportive care drugs, by

distribution channel

      • 7.4.2.6.Rest of Asia-Pacific
      • 7.4.2.6.1.Rest of Asia-Pacific cancer supportive care drugs, by type
      • 7.4.2.6.2.Rest of Asia-Pacific cancer supportive care drugs, by application
      • 7.4.2.6.3.Rest of Asia-Pacific cancer supportive care drugs, by distribution channel
    • 7.4.3.Asia-Pacific market size and forecast, by type
    • 7.4.4.Asia-Pacific market size and forecast, by application
    • 7.4.5.Asia-Pacific market size and forecast, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country201
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil cancer supportive care drugs, by type
      • 7.5.2.1.2.Brazil cancer supportive care drugs, by application
      • 7.5.2.1.3.Brazil cancer supportive care drugs, by distribution

channel

      • 7.5.2.2.Saudi Arabia
      • 7.5.2.2.1.Saudi Arabia cancer supportive care drugs, by type
      • 7.5.2.2.2.Saudi Arabia cancer supportive care drugs, by application
      • 7.5.2.2.3.Saudi Arabia cancer supportive care drugs, by

distribution channel

      • 7.5.2.3.South Africa
      • 7.5.2.3.1.South Africa cancer supportive care drugs, by type
      • 7.5.2.3.2.South Africa cancer supportive care drugs, by application
      • 7.5.2.3.3.South Africa cancer supportive care drugs, by

distribution channel

      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA cancer supportive care drugs, by type
      • 7.5.2.4.2.Rest of LAMEA cancer supportive care drugs, by

application

      • 7.5.2.4.3.Rest of LAMEA cancer supportive care drugs, by

distribution channel

    • 7.5.3.LAMEA market size and forecast, by type
    • 7.5.4.LAMEA market size and forecast, by application
    • 7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.AMGEN INC.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.BAXTER INTERNATIONAL INC.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product Portfolio
    • 8.2.5.Business performance
  • 8.3.F. HOFFMANN-LA ROCHE LTD.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance.
  • 8.4.GLAXOSMITHKLINE PLC (GSK) (TESASRO)
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance.
  • 8.5.HELSINN HEALTHCARE
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
  • 8.6.HERON THERAPEUTICS
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.MERCK KGAA
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product Portfolio
    • 8.8.5.Business performance
  • 8.9.NOVARTIS INTERNATIONAL AG (SANDOZ)
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.TEVA PHARMACEUTICALS
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
Back to Top
전화 문의
F A Q